It is known that translocation of BCL-2 and c-MYC genes leads to constitutive activation of both proteins, a key feature of GCB-DLBCL subtype.14 We found that SNS-032 treatment attenuated the protein level of c-MYC with a dose- and time-dependent manner in both SU-DHL-4 and SU-DHL-2 cell lines. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.